Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117175) titled 'Comparison of aspirin and rivaroxaban for the prevention of pulmonary embolism and deep vein thrombosis in high thrombotic risk patients with systemic lupus erythematosus (PREVENT-SLE)' on Jan. 20.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The Second Xiangya Hospital of Central South University
Condition:
Systemic lupus erythematosus
Intervention:
Aspirin group:Take 100mg of aspirin per day
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-01-21
Target Sample Size: Aspirin group:228;Rivaroxaban group:228;
Countries of Recruitment:
China
To ...